522 related articles for article (PubMed ID: 21413904)
1. Liposomal vaccine delivery systems.
Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
[TBL] [Abstract][Full Text] [Related]
2. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
[TBL] [Abstract][Full Text] [Related]
3. Cationic liposomes as vaccine adjuvants.
Christensen D; Korsholm KS; Andersen P; Agger EM
Expert Rev Vaccines; 2011 Apr; 10(4):513-21. PubMed ID: 21506648
[TBL] [Abstract][Full Text] [Related]
4. An overview of adjuvant formulations and delivery systems.
García A; De Sanctis JB
APMIS; 2014 Apr; 122(4):257-67. PubMed ID: 23919674
[TBL] [Abstract][Full Text] [Related]
5. Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status.
Korsholm KS; Andersen PL; Christensen D
Expert Rev Vaccines; 2012 May; 11(5):561-77. PubMed ID: 22827242
[TBL] [Abstract][Full Text] [Related]
6. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
Nordly P; Madsen HB; Nielsen HM; Foged C
Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037
[TBL] [Abstract][Full Text] [Related]
7. Cationic liposomes as vaccine adjuvants.
Christensen D; Korsholm KS; Rosenkrands I; Lindenstrøm T; Andersen P; Agger EM
Expert Rev Vaccines; 2007 Oct; 6(5):785-96. PubMed ID: 17931158
[TBL] [Abstract][Full Text] [Related]
8. Particulate delivery systems for vaccines: what can we expect?
Bramwell VW; Perrie Y
J Pharm Pharmacol; 2006 Jun; 58(6):717-28. PubMed ID: 16734973
[TBL] [Abstract][Full Text] [Related]
9. Liposome-based delivery system for vaccine candidates: constructing an effective formulation.
Giddam AK; Zaman M; Skwarczynski M; Toth I
Nanomedicine (Lond); 2012 Dec; 7(12):1877-93. PubMed ID: 23249332
[TBL] [Abstract][Full Text] [Related]
10. An overview on liposomal delivery and adjuvant development for leishmaniosis vaccines.
Soosaraei M; Hezarjaribi HZ; Fakhar M; Akhtari J; Emameh RZ
Ann Parasitol; 2021; 67(3):367-386. PubMed ID: 34953114
[TBL] [Abstract][Full Text] [Related]
11. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.
Watson DS; Endsley AN; Huang L
Vaccine; 2012 Mar; 30(13):2256-72. PubMed ID: 22306376
[TBL] [Abstract][Full Text] [Related]
12. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.
Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D
J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684
[TBL] [Abstract][Full Text] [Related]
13. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog.
Christensen D; Henriksen-Lacey M; Kamath AT; Lindenstrøm T; Korsholm KS; Christensen JP; Rochat AF; Lambert PH; Andersen P; Siegrist CA; Perrie Y; Agger EM
J Control Release; 2012 Jun; 160(3):468-76. PubMed ID: 22709414
[TBL] [Abstract][Full Text] [Related]
14. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
De Magistris MT
Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
[TBL] [Abstract][Full Text] [Related]
15. Adjuvants and delivery systems in veterinary vaccinology: current state and future developments.
Heegaard PM; Dedieu L; Johnson N; Le Potier MF; Mockey M; Mutinelli F; Vahlenkamp T; Vascellari M; Sørensen NS
Arch Virol; 2011 Feb; 156(2):183-202. PubMed ID: 21170730
[TBL] [Abstract][Full Text] [Related]
16. Biomaterials as vaccine adjuvants.
Jones KS
Biotechnol Prog; 2008; 24(4):807-14. PubMed ID: 19194892
[TBL] [Abstract][Full Text] [Related]
17. Archaeosomes with encapsulated antigens for oral vaccine delivery.
Li Z; Zhang L; Sun W; Ding Q; Hou Y; Xu Y
Vaccine; 2011 Jul; 29(32):5260-6. PubMed ID: 21609747
[TBL] [Abstract][Full Text] [Related]
18. Targeting strategies of liposomal subunit vaccine delivery systems to improve vaccine efficacy.
Yu R; Mai Y; Zhao Y; Hou Y; Liu Y; Yang J
J Drug Target; 2019 Aug; 27(7):780-789. PubMed ID: 30589361
[TBL] [Abstract][Full Text] [Related]
19. Immunity in response to particulate antigen-delivery systems.
Storni T; Kündig TM; Senti G; Johansen P
Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
[TBL] [Abstract][Full Text] [Related]
20. Adjuvants enhancing an integral immune response to antigens. 15-17 September, 2004, Modern Vaccine/Adjuvant Formulation: impact on future development (MVAF 2004), Prague.
van der Laan JW
Expert Rev Vaccines; 2005 Feb; 4(1):15-8. PubMed ID: 15757468
[No Abstract] [Full Text] [Related]
[Next] [New Search]
